Europe Autoimmune Disease Therapeutics Market By Indication (Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Other Indications) By Drug Class (Anti-Inflammatory, Anti-Hyperglycemics, NSAIDs Nonsteroidal anti-inflammatory drugs, Interferons and Other Drugs) By the Distribution Channel (Hospital Pharmacy, Online and Retail Pharmacies & Drug Stores)

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Autoimmune Disease Therapeutics Market, by Indication
1.4.2 Europe Autoimmune Disease Therapeutics Market, by Drug Class
1.4.3 Europe Autoimmune Disease Therapeutics Market, by Distribution Channel
1.4.4 Global Autoimmune Disease Therapeutics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Autoimmune Disease Therapeutics Market by Indication
3.1 Europe Rheumatic Disease Market by Country
3.2 Europe Diabetes Market by Country
3.3 Europe Multiple Sclerosis Market by Country
3.4 Europe Inflammatory Bowel Disease Market by Country
3.5 Europe Other Indications Market by Country
Chapter 4. Europe Autoimmune Disease Therapeutics Market by Drug Class
4.1 Europe Anti-Inflammatory Market by Country
4.2 Europe Anti-Hyperglycemics Market by Country
4.3 Europe NSAIDs Market by Country
4.4 Europe Interferons Market by Country
4.5 Europe Other Drugs Market by Country
Chapter 5. Europe Autoimmune Disease Therapeutics Market by Distribution Channel
5.1 Europe Hospital Pharmacy Market by Country
5.2 Europe Online Market by Country
5.3 Europe Retail Pharmacies and Drug Stores Market by Country
Chapter 6. Europe Autoimmune Disease Therapeutics Market by Country
6.1 Germany Autoimmune Disease Therapeutics Market
6.1.1 Germany Autoimmune Disease Therapeutics Market by Indication
6.1.2 Germany Autoimmune Disease Therapeutics Market by Drug Class
6.1.3 Germany Autoimmune Disease Therapeutics Market by Distribution Channel
6.2 UK Autoimmune Disease Therapeutics Market
6.2.1 UK Autoimmune Disease Therapeutics Market by Indication
6.2.2 UK Autoimmune Disease Therapeutics Market by Drug Class
6.2.3 UK Autoimmune Disease Therapeutics Market by Distribution Channel
6.3 France Autoimmune Disease Therapeutics Market
6.3.1 France Autoimmune Disease Therapeutics Market by Indication
6.3.2 France Autoimmune Disease Therapeutics Market by Drug Class
6.3.3 France Autoimmune Disease Therapeutics Market by Distribution Channel
6.4 Russia Autoimmune Disease Therapeutics Market
6.4.1 Russia Autoimmune Disease Therapeutics Market by Indication
6.4.2 Russia Autoimmune Disease Therapeutics Market by Drug Class
6.4.3 Russia Autoimmune Disease Therapeutics Market by Distribution Channel
6.5 Spain Autoimmune Disease Therapeutics Market
6.5.1 Spain Autoimmune Disease Therapeutics Market by Indication
6.5.2 Spain Autoimmune Disease Therapeutics Market by Drug Class
6.5.3 Spain Autoimmune Disease Therapeutics Market by Distribution Channel
6.6 Italy Autoimmune Disease Therapeutics Market
6.6.1 Italy Autoimmune Disease Therapeutics Market by Indication
6.6.2 Italy Autoimmune Disease Therapeutics Market by Drug Class
6.6.3 Italy Autoimmune Disease Therapeutics Market by Distribution Channel
6.7 Rest of Europe Autoimmune Disease Therapeutics Market
6.7.1 Rest of Europe Autoimmune Disease Therapeutics Market by Indication
6.7.2 Rest of Europe Autoimmune Disease Therapeutics Market by Drug Class
6.7.3 Rest of Europe Autoimmune Disease Therapeutics Market by Distribution Channel
Chapter 7. Company Profiles
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Bio-Rad Laboratories, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.3 Johnson and Johnson
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Collaborations, partnerships and agreements:
7.4 GlaxoSmithKline PLC (GSK)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Acquisition and mergers:
7.4.5.2 Collaborations, partnerships and agreements:
7.4.5.3 Product launches:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Approval:
7.6 Merck & Co., Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.7 Bayer AG (Bayer Schering Pharma AG)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Collaborations, partnerships and agreements:
7.8 AbbVie, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.9 Amgen, Inc.
7.9.1 Company overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Product launches:
7.9.5.2 Collaborations, partnerships and agreements:
7.1 Novartis AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Acquisition and mergers:
7.10.5.2 Collaborations, partnerships and agreements: